Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modafinil augmentation in chronic and refractory major depressive disorder
ChiCTR2000038989Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of modafinil in major depressive disorder (MDD), persistent depressive disorder (PDD) and treatment-resistant depression (TRD) (4 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: HAMD score reduction rate. Started Jul 2018; status: recruiting.
02
Drugs
modafinil
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2000038989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038989.